Abstract 468P
Background
Trametinib and dabrafenib have shown promising results in LGG and HGG treatment, which are common pediatric tumors. However, their toxicity profile in children has not been fully described.
Methods
The SACHA-France study is a prospective observational study open in all French Society of Pediatric Oncology (SFCE) centers, that collects safety and efficacy data of innovative drugs that are administered to patients ≤ 25 years-old with pediatric malignancies and prescribed either as compassionate or off-label use. All adverse-drug reactions (ADRs) for trametinib in combination with dabrafenib for LGG and HGG with BRAF mutation or trametinib monotherapy for LGG and HGG with BRAF fusion, wildtype LGG and NF1 LGG included in the study from January 2020 to March 2024 are analyzed herein.
Results
In total, 138 patients were included and received trametinib in combination with dabrafenib (cohort A, n=52) or trametinib monotherapy (cohort B, n= 86).
In cohort A, median age was 12.7 years (range: 4.0 – 25.4) and median treatment duration was 24.7 months (range: 1.1 – 48.8). Overall, 32.7% of patients experienced at least one ADR of grade ≥ 2, leading to treatment discontinuation in 3 patients. Six serious ADRs (SADRs) were reported in 3 patients. No grade 5 ADRs were reported. The most common ADRs were skin toxicities (11.5%) and general disorders (13.56%), mainly fever.
In cohort B, median age was 11.3 years (range: 2.1 – 20.6) and median treatment duration was 14.9 months (range: 1.0 – 38.4). Overall, 72.1% of patients presented at least one ADR of grade 2-3, leading to treatment discontinuation in 8 patients. Six SADRs were reported in 4 patients. No grade 4-5 ADRs were reported. The main ADRs were skin (53.5%) and gastrointestinal disorders (11.6%).
Conclusions
To our knowledge, this is the first comprehensive nation-wide study on the safety profile of trametinib and dabrafenib in the pediatric and young adult population. Our data confirm, in the real-life setting, a safety profile similar to that described in previous pediatric studies and in adult patients.
SACHA-France is supported by Imagine for Margo, Association Hubert Gouin, Fondation du LEEM and the SFCE.
Clinical trial identification
NCT04477681.
Editorial acknowledgement
Legal entity responsible for the study
P. Berlanga.
Funding
SACHA-France is supported by Imagine for Margo, Association Hubert Gouin, Fondation du LEEM and the SFCE.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
547P - Artificial Intelligence-powered analysis of the tumor immune microenvironment in primary and metastatic colorectal cancer
Presenter: Elio Adib
Session: Poster session 16
548P - Simplified immune score based on CD8+ T-cells at the invasive margin provides comparable prognostic value to immune scores in non-metastatic colorectal cancer
Presenter: Durgesh Wankhede
Session: Poster session 16
549P - Combined morphometric immune signatures define the prognosis of patients with resectable colorectal liver metastases
Presenter: Markus Moehler
Session: Poster session 16
550P - The impact of mismatch repair status on accuracy of clinical staging in upfront resected stage II/III rectal cancer in the Netherlands
Presenter: Renee Lunenberg
Session: Poster session 16
551P - Efficacy prediction of chemoradiotherapy plus anti-PD-1/PD-L1 treatment by magnetic resonance imaging in MSS locally advanced rectal cancer
Presenter: Wentao Tang
Session: Poster session 16
552P - Baseline imaging biomarkers to predict outcomes in locally advanced colon cancer (LACC): Data from the FOxTROT international randomised-controlled trial
Presenter: James Platt
Session: Poster session 16
553P - Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
Presenter: JUN NAGATA
Session: Poster session 16
555P - Association between copy number aberration and ctDNA MRD in colorectal cancer: CIRCULATE-Japan GALAXY
Presenter: TOMOYA HARIMA
Session: Poster session 16